Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $10,500 | 2 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $10,500 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2018 | $2,800 | 1 | NOVARTIS PHARMACEUTICALS CORPORATION ($2,800) |
| 2017 | $7,700 | 1 | NOVARTIS PHARMACEUTICALS CORPORATION ($7,700) |
All Payment Transactions
2 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/15/2018 | NOVARTIS PHARMACEUTICALS CORPORATION | EXJADE (Drug) | — | Cash or cash equivalent | $2,800.00 | Research |
| Study: A MULTI CENTER RANDOMIZED DOUBLE BLIND PLACEBOCONTROLLED CLINICAL TRIAL OF DEFERASIROX IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES LOW INT1 RISK AND TRANSFUSIONAL IRON OVERLOAD TELESTO • Category: HEMATOLOGY | ||||||
| 01/03/2017 | NOVARTIS PHARMACEUTICALS CORPORATION | EXJADE (Drug) | — | Cash or cash equivalent | $7,700.00 | Research |
| Study: A MULTI CENTER RANDOMIZED DOUBLE BLIND PLACEBOCONTROLLED CLINICAL TRIAL OF DEFERASIROX IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES LOW INT1 RISK AND TRANSFUSIONAL IRON OVERLOAD TELESTO • Category: HEMATOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTI CENTER RANDOMIZED DOUBLE BLIND PLACEBOCONTROLLED CLINICAL TRIAL OF DEFERASIROX IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES LOW INT1 RISK AND TRANSFUSIONAL IRON OVERLOAD TELESTO | NOVARTIS PHARMACEUTICALS CORPORATION | $10,500 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 1,276 | 1,339 | $448,163 | $84,580 |
| 2022 | 15 | 1,398 | 1,506 | $490,606 | $92,901 |
| 2021 | 17 | 1,341 | 1,447 | $478,205 | $93,353 |
| 2020 | 14 | 1,185 | 1,382 | $432,666 | $88,849 |
All Medicare Procedures & Services
65 procedure records from CMS Medicare Utilization — Page 2 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 64 | 65 | $5,980 | $808.39 | 13.5% |
| 93320 | Ultrasound of heart blood flow, valves and chambers | Facility | 2022 | 48 | 48 | $3,396 | $739.90 | 21.8% |
| 93350 | Ultrasound of heart during rest, exercise and/or drug-induced stress with report | Facility | 2022 | 13 | 13 | $3,634 | $630.37 | 17.3% |
| 93321 | Ultrasound of heart blood flow, valves and chambers, follow-up | Facility | 2022 | 67 | 68 | $1,922 | $413.09 | 21.5% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Facility | 2022 | 110 | 111 | $1,554 | $293.16 | 18.9% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2022 | 14 | 14 | $1,220 | $241.95 | 19.8% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2022 | 14 | 14 | $1,960 | $161.77 | 8.3% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Facility | 2021 | 599 | 607 | $182,100 | $35,113 | 19.3% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Office | 2021 | 161 | 162 | $110,592 | $20,386 | 18.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 48 | 132 | $38,496 | $8,209 | 21.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 69 | 74 | $35,095 | $7,838 | 22.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 38 | 38 | $31,206 | $6,587 | 21.1% |
| 93355 | Insertion of probe in esophagus for heart ultrasound examination during procedure on heart or great blood vessel via catheter | Facility | 2021 | 31 | 31 | $28,906 | $5,835 | 20.2% |
| 93314 | Interpretation and report of heart ultrasound examination using esophageal probe | Facility | 2021 | 38 | 39 | $15,444 | $2,902 | 18.8% |
| 93312 | Insertion of probe in esophagus for heart ultrasound examination including interpretation and report | Facility | 2021 | 13 | 13 | $5,797 | $1,226 | 21.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 14 | 14 | $6,370 | $1,115 | 17.5% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 70 | 74 | $6,518 | $931.55 | 14.3% |
| 93350 | Ultrasound examination of the heart performed during rest, exercise, and/or drug-induced stress with interpretation and report | Facility | 2021 | 16 | 16 | $4,596 | $859.46 | 18.7% |
| 93320 | Doppler ultrasound study of heart blood flow, valves, and chambers | Facility | 2021 | 44 | 45 | $3,315 | $692.12 | 20.9% |
| 93308 | Follow-up or limited ultrasound examination of heart | Facility | 2021 | 25 | 25 | $2,575 | $528.72 | 20.5% |
| 93016 | Exercise or drug-induced heart and blood vessel stress test with ekg monitoring and physician supervision | Facility | 2021 | 17 | 17 | $1,527 | $285.30 | 18.7% |
| 93321 | Follow-up or limited heart doppler ultrasound study of heart blood flow, valves, and chambers | Facility | 2021 | 41 | 41 | $1,208 | $239.40 | 19.8% |
| 76376 | 3d radiographic procedure | Facility | 2021 | 26 | 26 | $1,016 | $219.44 | 21.6% |
| 93325 | Doppler ultrasound study of color-directed heart blood flow, rate, and valve function | Facility | 2021 | 74 | 76 | $1,064 | $195.84 | 18.4% |
| 93018 | Exercise or drug-induced heart and blood vessel stress test with ekg monitoring, physician interpretation and report | Facility | 2021 | 17 | 17 | $2,380 | $190.65 | 8.0% |
About Dr. Danita Sanborn, MD
Dr. Danita Sanborn, MD is a Internal Medicine healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/04/2005. The National Provider Identifier (NPI) number assigned to this provider is 1770574071.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Danita Sanborn, MD has received a total of $10,500 in payments from pharmaceutical and medical device companies, with $2,800 received in 2018. These payments were reported across 2 transactions from 1 company. The most common payment nature is "" ($10,500).
As a Medicare-enrolled provider, Sanborn has provided services to 5,200 Medicare beneficiaries, totaling 5,674 services with total Medicare billing of $359,683. Data is available for 4 years (2020–2023), covering 65 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Cardiovascular Disease
- Location Boston, MA
- Active Since 11/04/2005
- Last Updated 04/08/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1770574071
Products in Payments
- EXJADE (Drug) $10,500
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Boston
Michael Mendelsohn, M.d, M.D
Internal Medicine — Payments: $4.6M
David Schenkein, Md, MD
Internal Medicine — Payments: $4.0M
Dr. John Fallon, M.d, M.D
Internal Medicine — Payments: $2.5M
Dr. David Scadden, Md, MD
Internal Medicine — Payments: $2.2M
Dr. James Januzzi, Md, MD
Internal Medicine — Payments: $1.8M
Dr. Marilyn Pike, Md Phd, MD PHD
Internal Medicine — Payments: $1.5M